Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Nebraska Oncology Society
E

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy of New RET Inhibitors? Should We Use Them 1L or 2L?

By Nebraska Oncology Society FEATURING Eric Sherman
By Nebraska Oncology Society FEATURING Eric Sherman
17 views
January 5, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Head and Neck
08:09
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "AIM-HN Study Evaluating Tipifarnib in mHRA…

Feat. A. Ho
18:07
Nebraska Oncology Society

NOS ASCO® 2023 Review: Nasopharynx Cancer

Feat. E. Sherman
22:27
Nebraska Oncology Society

NOS ASCO® 2023 Review: Head & Neck Cancer De-Escalation

Feat. E. Sherman
47:18
Nebraska Oncology Society

ASCO 2022 Review of Head & Neck Cancer Updates

Feat. E. Sherman
09:41
Nebraska Oncology Society

ASCO 2020 Review of Transoral Robotic Surgery for OPC : Is 2-yr PFS …

Feat. E. Sherman
09:24
Nebraska Oncology Society

2020 ASCO LA-HNSCC Trials Review: What Is the Efficacy of Weekly CDD…

Feat. E. Sherman
11:38
Nebraska Oncology Society

ASCO 2020 Update on DO-IMRT & HNC Metastatic: Does Change in IMR…

Feat. E. Sherman
04:56
Nebraska Oncology Society

2020 ASCO Update on Metastatic/Recurrent HNSCC: What Is the Efficacy…

Feat. E. Sherman
08:09
Nebraska Oncology Society

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy…

Feat. E. Sherman